Mounjaro vs Wegovy is one of the most important comparisons for patients seeking weight management medication. Both are once-weekly injections, both are extraordinarily effective compared to older weight loss drugs, and both come from the two biggest names in metabolic medicine: Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy). The clinical data tells a clear story: Mounjaro generally produces greater weight loss, but Wegovy has more long-term safety data and unique cardiovascular outcomes evidence. Here's the complete editorial breakdown.
Quick Overview: Mounjaro vs Wegovy
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide 2.4mg | Tirzepatide |
| Drug class | GLP-1 only | GLP-1 + GIP dual |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Average weight loss | ~15% body weight | ~15-22% body weight |
| FDA approval | 2021 (weight loss) | 2022 (T2D) |
The most consequential difference is the mechanism (single GLP-1 vs dual GLP-1/GIP) and the resulting weight loss magnitude. Mounjaro typically produces 5-7 percentage points more weight loss than Wegovy at maximum doses.
Weight Loss: Mounjaro vs Wegovy
The clearest differentiator between Mounjaro and Wegovy is the magnitude of weight loss. Both are dramatically more effective than older weight loss medications, but Mounjaro consistently outperforms Wegovy in clinical trial data.
| Time Point | Wegovy 2.4mg | Mounjaro 15mg |
|---|---|---|
| 12 weeks | ~6% body weight | ~10% body weight |
| 6 months | ~10% body weight | ~17% body weight |
| 12 months | ~14% body weight | ~21% body weight |
| 18 months (72 weeks) | ~15% body weight | ~22.5% body weight |
For a 250-pound starting weight, that translates to approximately 38 pounds on Wegovy vs 56 pounds on Mounjaro at 18 months — an additional 18 pounds of weight loss with Mounjaro. The difference is real, statistically significant, and clinically meaningful.
It's worth noting that Wegovy is the FDA-approved weight management brand of semaglutide. The same molecule is also marketed as Ozempic for type 2 diabetes at lower doses. For weight loss, Wegovy 2.4mg is the higher and more effective dose.
Why Mounjaro Outperforms Wegovy Mechanistically
The fundamental difference between Mounjaro and Wegovy is the receptor target.
Wegovy activates only the GLP-1 receptor. This single-receptor mechanism produces strong appetite suppression, slowed gastric emptying, and improved insulin response — all the standard GLP-1 effects.
Mounjaro activates both the GLP-1 and GIP receptors simultaneously. The addition of GIP receptor activation enhances metabolic effects in ways that go beyond what GLP-1 alone can produce. The result is greater weight loss and slightly better blood sugar control across virtually every measured outcome.
The dual mechanism isn't just additive — there's evidence of synergy. Researchers don't yet fully understand why combining GLP-1 and GIP activation produces effects larger than the sum of either alone, but the clinical results consistently show that it does.
Side Effects: Mounjaro vs Wegovy
Both medications have similar side effect profiles dominated by gastrointestinal symptoms. Comparing the published trial data:
| Side Effect | Wegovy | Mounjaro |
|---|---|---|
| Nausea | 44% | 29% |
| Diarrhea | 30% | 21% |
| Vomiting | 24% | 15% |
| Constipation | 24% | 13% |
| Abdominal pain | 20% | 10% |
| Fatigue | 11% | 10% |
Interestingly, the published data suggests Wegovy has slightly higher rates of GI side effects than Mounjaro, despite producing less weight loss. This may be related to the slower escalation schedule used in SURMOUNT trials, or to differences in how the dual GLP-1/GIP mechanism affects gastric emptying compared to GLP-1 alone. Either way, neither medication is "easier" on a typical patient.
Cost Comparison: Mounjaro vs Wegovy
| Cost Scenario | Wegovy | Mounjaro |
|---|---|---|
| List price | ~$1,349/month | ~$1,069/month |
| With manufacturer savings card | ~$0-$25/month | ~$25/month |
| Average insurance copay | $25-$300 | $25-$300 |
| Telehealth cash pay | $300-$500 | $400-$600 |
| Manufacturer assistance program | Novo Nordisk PAP | Lilly Cares Foundation |
Wegovy has the higher list price but its savings card programs are competitive. Mounjaro and Zepbound (the weight loss brand of tirzepatide) have similar list prices but slightly different savings programs. For most patients with insurance, the actual out-of-pocket cost is similar between the two — usually $25-$300/month depending on plan and savings card eligibility.
Which Should You Choose: Mounjaro or Wegovy?
The honest answer depends on several factors:
Choose Mounjaro/Zepbound If…
- You want maximum weight loss
- You\'ve tried Wegovy and want greater results
- Your insurance covers Mounjaro/Zepbound but not Wegovy
- You prefer the most current and most effective option in the GLP-1 class
Choose Wegovy If…
- You have established cardiovascular disease (Wegovy has cardiovascular outcomes data from SELECT trial)
- Your insurance covers Wegovy but not Mounjaro/Zepbound
- You prefer a drug with longer post-market safety data (semaglutide has been on the market longer than tirzepatide)
- You\'ve responded well to other Novo Nordisk products historically
The Editorial View
For most patients seeking weight loss without unique cardiovascular indications, Mounjaro/Zepbound is the more effective choice based on direct comparison of clinical trial results. The dual-receptor mechanism produces meaningfully greater weight loss without meaningfully greater side effect burden. Wegovy remains an excellent option, particularly for patients with cardiovascular disease where its outcomes data is uniquely strong. But if pure weight loss magnitude is the goal and you don\'t have specific reasons to prefer semaglutide, Mounjaro is generally the right call.
Frequently Asked Questions
Frequently Asked Questions
Is Mounjaro better than Wegovy for weight loss?
In clinical trials, Mounjaro (tirzepatide) consistently produces greater weight loss than Wegovy (semaglutide 2.4mg). The SURMOUNT-1 trial showed average weight loss of 22.5% on Mounjaro 15mg vs approximately 15% on Wegovy 2.4mg in the STEP-1 trial. The dual GLP-1/GIP mechanism of tirzepatide is the primary reason for the difference.
What's the difference between Mounjaro and Wegovy?
Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist. Wegovy contains semaglutide 2.4mg, a single GLP-1 agonist. Both are once-weekly injections, both come from major manufacturers (Eli Lilly vs Novo Nordisk), and both produce significant weight loss. The mechanism difference (single vs dual receptor) is the main distinction.
Can I take Mounjaro and Wegovy together?
No. Both drugs are GLP-1 receptor agonists and combining them produces severe side effects without additional benefit. Patients should be on one or the other, not both. Switching between them is straightforward and common, but never combine.
Is Wegovy cheaper than Mounjaro?
List prices are similar — Wegovy is approximately $1,349/month, Mounjaro is approximately $1,069/month. Insurance coverage and savings card programs determine the actual out-of-pocket cost. Both have manufacturer savings cards that can reduce costs significantly for commercially insured patients.